OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology for evaluation of safety and efficacy in Cancer. TAIPEI, Taiwan, Sep 02, 2025, ─ OBI Pharma, a clinical-stage oncology company (4174.TWO), today announced the initiation of a Phase 1/2 clinical trial of OBI-902, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast cell-surface antigen 2), […]

HOMEWhat’s NewNewsOBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2025.Jul.22

OBI Pharma Showcases Innovative Pipeline, Platforms, and Technologies at BIO Asia–Taiwan 2025 GlycOBI® and HYPrOBI™ Drive the Advancement of Bispecific, Dual-Payload ADCs

2025.Sep.01

OBI Pharma, Inc. Announces Board Resolution for Capital Reduction to Offset Accumulated Losses and Holds Material Information Press Conference